TD Cowen raised the firm’s price target on Biohaven to $55 from $35 and keeps an Outperform rating on the shares. The firm said its BHV-1300 SAD/IgG depletion and initial clinical data are expected by March/April and they believe that shares could double on very positive data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHVN:
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Biohaven price target raised to $56 from $32 at JPMorgan
- UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
- RBC Capital starts Biohaven at Outperform, sees BHV-7000 with over $1B potential